Modeling polyglutamine pathogenesis in C. elegans
- PMID: 17046663
- DOI: 10.1016/S0076-6879(06)12016-9
Modeling polyglutamine pathogenesis in C. elegans
Abstract
A growing number of human neurodegenerative diseases are associated with disruption of cellular protein folding homeostasis, leading to the appearance of misfolded proteins and deposition of protein aggregates and inclusions. Recent years have been witness to widespread development of invertebrate systems (specifically Drosophila and Caenorhabditis elegans) to model these disorders, bringing the many advantages of such systems, particularly the power of genetic analysis in a metazoan, to bear on these problems. In this chapter, we describe our studies using the nematode, C. elegans, as a model to study polyglutamine expansions as occur in Huntington's disease and related ataxias. Using fluorescently tagged polyglutamine repeats of different lengths, we have examined the dynamics of aggregate formation both within individual cells and over time throughout the lifetime of individual organisms, identifying aging as an important physiological determinant of aggregation and toxicity. Expanding on these observations, we demonstrate that a genetic pathway regulating longevity can alter the time course of aging-related polyglutamine-mediated phenotypes. To identify novel targets and better understand how cells sense and respond to the appearance of misfolded and aggregation-prone proteins, we use a genome-wide RNA interference-based genetic screen to identify modifiers of age-dependent polyglutamine aggregation. Throughout these studies, we used fluorescence-based, live-cell biological and biophysical methods to study the behavior of these proteins in a complex multicellular environment.
Similar articles
-
The stress of misfolded proteins: C. elegans models for neurodegenerative disease and aging.Adv Exp Med Biol. 2007;594:167-89. doi: 10.1007/978-0-387-39975-1_15. Adv Exp Med Biol. 2007. PMID: 17205684 Review.
-
The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans.Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10417-22. doi: 10.1073/pnas.152161099. Epub 2002 Jul 16. Proc Natl Acad Sci U S A. 2002. PMID: 12122205 Free PMC article.
-
Progressive disruption of cellular protein folding in models of polyglutamine diseases.Science. 2006 Mar 10;311(5766):1471-4. doi: 10.1126/science.1124514. Epub 2006 Feb 9. Science. 2006. PMID: 16469881
-
Studying polyglutamine aggregation in Caenorhabditis elegans using an analytical ultracentrifuge equipped with fluorescence detection.Protein Sci. 2016 Mar;25(3):605-17. doi: 10.1002/pro.2854. Epub 2015 Dec 21. Protein Sci. 2016. PMID: 26647351 Free PMC article.
-
Regulation of protein homeostasis in neurodegenerative diseases: the role of coding and non-coding genes.Cell Mol Life Sci. 2015 Nov;72(21):4027-47. doi: 10.1007/s00018-015-1985-0. Epub 2015 Jul 21. Cell Mol Life Sci. 2015. PMID: 26190021 Free PMC article. Review.
Cited by
-
Widespread protein aggregation as an inherent part of aging in C. elegans.PLoS Biol. 2010 Aug 10;8(8):e1000450. doi: 10.1371/journal.pbio.1000450. PLoS Biol. 2010. PMID: 20711477 Free PMC article.
-
Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs).Chem Rev. 2014 Jul 9;114(13):6661-714. doi: 10.1021/cr400695p. Epub 2014 Jun 5. Chem Rev. 2014. PMID: 24901537 Free PMC article. Review. No abstract available.
-
3β-Hydroxy-urs-12-en-28-oic Acid Modulates Dietary Restriction Mediated Longevity and Ameliorates Toxic Protein Aggregation in C. elegans.J Gerontol A Biol Sci Med Sci. 2017 Nov 9;72(12):1614-1619. doi: 10.1093/gerona/glx118. J Gerontol A Biol Sci Med Sci. 2017. PMID: 28673026 Free PMC article.
-
NRFL-1, the C. elegans NHERF orthologue, interacts with amino acid transporter 6 (AAT-6) for age-dependent maintenance of AAT-6 on the membrane.PLoS One. 2012;7(8):e43050. doi: 10.1371/journal.pone.0043050. Epub 2012 Aug 15. PLoS One. 2012. PMID: 22916205 Free PMC article.
-
C. elegans in high-throughput drug discovery.Adv Drug Deliv Rev. 2014 Apr;69-70:247-53. doi: 10.1016/j.addr.2013.12.001. Epub 2013 Dec 12. Adv Drug Deliv Rev. 2014. PMID: 24333896 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
